Cost-effectiveness of abatacept, rituximab, and tnfi treatment after previous failure with tnfi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

HIGHLIGHTS

• who: Sofie HM Manders from the The primary outcome for effectiveness was the , [16] over timeThe secondary outcome measures were functional ability measured using the Health Assessment Questionnaire Disability Index (HAQ-DI) [17] and generic descriptive quality of life (36-item Short Form Health Survey (SF-36)) [18]. All effectiveness outcomes were measured at, , and , months. The outcomes for the cost-effectiveness analysis were medication costs and quality-adjusted life-years (QALYs) over a, month period. QALYs were based on utilities (a numeric value ranging from , to, .0, reflecting health status: , indicates death, and, ., indicates the best . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.